이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PAVmed 관리

관리 기준 확인 2/4

PAVmed's CEO는 Lishan Aklog, Jun2014 에 임명되었습니다 의 임기는 10.08 년입니다. 총 연간 보상은 $ 953.20K, 95.8% 로 구성됩니다. 95.8% 급여 및 4.2% 보너스(회사 주식 및 옵션 포함). 는 $ 306.30K 가치에 해당하는 회사 주식의 3.98% 직접 소유합니다. 306.30K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 9.5 년입니다.

주요 정보

Lishan Aklog

최고 경영자

US$953.2k

총 보상

CEO 급여 비율	95.8%
CEO 임기	10.1yrs
CEO 소유권	4.0%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	9.5yrs

최근 관리 업데이트

Recent updates

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

Jul 05

Start Accumulating PAVmed

Dec 24

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

Sep 02

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Aug 23

PAVmed: A True Game-Changer For Medical Device Innovation

Jun 14

PAVmed forms digital health company, Veris Health

Jun 02

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

May 26

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

May 19

PAVmed drops 14% on launch of $13.4M direct offering

Jan 06

PAVmed closes additional direct offering of common stock

Dec 22

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

Dec 16

PAVmed offers stock for $8.9M

Dec 11

PAVmed EPS beats by $0.02

Nov 17

There Is Progress At PAVmed, But More Patience Is Required

Oct 30

CEO 보상 분석

Lishan Aklog 의 보수는 PAVmed 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$71m
Dec 31 2023	US$953k	US$913k	-US$66m
Sep 30 2023	n/a	n/a	-US$71m
Jun 30 2023	n/a	n/a	-US$79m
Mar 31 2023	n/a	n/a	-US$90m
Dec 31 2022	US$1m	US$901k	-US$89m
Sep 30 2022	n/a	n/a	-US$86m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$58m
Dec 31 2021	US$9m	US$583k	-US$51m
Sep 30 2021	n/a	n/a	-US$42m
Jun 30 2021	n/a	n/a	-US$35m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$1m	US$431k	-US$35m
Sep 30 2020	n/a	n/a	-US$32m
Jun 30 2020	n/a	n/a	-US$30m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$890k	US$431k	-US$17m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$772k	US$346k	-US$19m
Sep 30 2018	n/a	n/a	-US$12m
Jun 30 2018	n/a	n/a	-US$14m
Mar 31 2018	n/a	n/a	-US$10m
Dec 31 2017	US$444k	US$297k	-US$10m

보상 대 시장: Lishan 의 총 보상 ($USD 953.20K )은 US 시장( $USD 683.56K ).

보상과 수익: Lishan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Lishan Aklog (58 yo)

10.1yrs

테뉴어

US$953,200

보상

Dr. Lishan Aklog, M.D., serves as Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. Aklo...

리더십 팀

이름	위치	테뉴어	보상	소유권
Lishan Aklog	Chairman & CEO	10.1yrs	US$953.20k	3.98% $ 266.1k
Dennis McGrath	President & CFO	7.3yrs	US$673.50k	0.54% $ 36.0k
Shaun O'Neill	Executive VP & COO	2.4yrs	US$498.00k	0.19% $ 12.7k
Michael Gordon	Executive VP	2.2yrs	US$710.50k	0% $ 0
Brian deGuzman	Executive VP	1.3yrs	US$593.10k	0% $ 0
Suman Verma	Senior VP of Molecular Genetics & Chief Scientific Officer	1.5yrs	데이터 없음	데이터 없음
Michael Parks	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Deepika Lakhani	Senior VP	1.5yrs	데이터 없음	데이터 없음
Victoria Lee	Senior VP & Chief Medical Officer	1.5yrs	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: PAVM 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Lishan Aklog	Chairman & CEO	10.1yrs	US$953.20k	3.98% $ 266.1k
Ronald Sparks	Independent Director	9.5yrs	US$251.90k	0.69% $ 46.0k
Todd Rosengart	Member of Medical Advisory Board	9.7yrs	데이터 없음	데이터 없음
Timothy Baxter	Independent Director	3.1yrs	US$238.90k	0.69% $ 46.0k
James Cox	Independent Director	9.5yrs	US$228.90k	0.69% $ 46.0k
Marc Gerdisch	Member of Medical Advisory Board	9.7yrs	데이터 없음	데이터 없음
Philip Stieg	Member of Medical Advisory Board	9.5yrs	데이터 없음	데이터 없음
Albert Chin	Member of Medical Advisory Board	9.5yrs	데이터 없음	데이터 없음
Michael Glennon	Independent Vice Chairman	9.8yrs	US$228.90k	0.87% $ 57.8k
Timothy Murphy	Member of Medical Advisory Board	9.7yrs	데이터 없음	데이터 없음
Debra White	Independent Director	3.3yrs	US$248.90k	0.69% $ 46.0k
Christopher Hartnick	Member of Medical Advisory Board	7.7yrs	데이터 없음	데이터 없음

9.5yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: PAVM 의 이사회는 경험(평균 재직 기간 9.4 년)으로 간주됩니다.

PAVmed 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Pavmed Inc. Appoints Dennis Matheis to Board of Directors

PAVmed Inc., Annual General Meeting, Jun 20, 2024

Independent Vice Chairman recently bought US$161k worth of stock

PAVmed Inc., Annual General Meeting, Jun 21, 2022

PAVmed Inc. Appoints Shaun O’Neil as Executive Vice President and Chief Operating Officer

Recent updates

Lucid Diagnostics Announces Positive Data from Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population

Insufficient new directors

New major risk - Market cap size

Consensus EPS estimates fall by 13%, revenue upgraded

Price target decreased by 21% to US$13.00

Pavmed Inc. Appoints Dennis Matheis to Board of Directors

PAVmed Inc., Annual General Meeting, Jun 20, 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 21% to US$16.38

Full year 2023 earnings: EPS exceeds analyst expectations

PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

PAVmed Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value of the Company’s Listed Securities Under Nasdaq Listing Rule 5550(b)(2)

New major risk - Share price stability

Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?

Now 24% undervalued after recent price drop

Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Price target decreased by 48% to US$20.63

Pavmed Inc. Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Pre Cancer Detection

Consensus revenue estimates decrease by 12%

New major risk - Negative shareholders equity

PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 35%

Consensus revenue estimates decrease by 40%, EPS upgraded

Consensus revenue estimates increase by 33%

No longer forecast to breakeven

PAVmed Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Independent Vice Chairman recently bought US$161k worth of stock

Price target decreased to US$5.06

Consensus forecasts updated

Consensus forecasts updated

Consensus revenue estimates fall by 80%

Price target decreased to US$5.50

Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?

PAVmed Non-GAAP EPS of -$0.17 beats by $0.03

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 2000 Dynamic Index

PAVmed Inc., Annual General Meeting, Jun 21, 2022

PAVmed Inc. announced delayed annual 10-K filing

Consensus revenue estimates fall by 10%

Price target decreased to US$8.13

PAVmed Inc. Appoints Shaun O’Neil as Executive Vice President and Chief Operating Officer

PAVmed Inc. Appoints Joan Harvey to Its Board of Directors

Start Accumulating PAVmed

Consensus forecasts updated

Price target increased to US$9.50

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Consensus revenue estimates fall to US$1.02m

Independent Director David Battleman has left the company

Independent Director David Weild has left the company

PAVmed: A True Game-Changer For Medical Device Innovation

Consensus forecasts updated

PAVmed forms digital health company, Veris Health

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $41.576088 million.

Price target raised to US$6.42

First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device

New 90-day high: US$2.68

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $13.44 million.

PAVmed drops 14% on launch of $13.4M direct offering

New 90-day high: US$2.13

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $8.1 million.

PAVmed closes additional direct offering of common stock

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

PAVmed offers stock for $8.9M

New 90-day high: US$2.06